Human VEGF Monoclonal Antibody
Product Sizes
1 mg
£268.00
YR0008-1MG
5 mg
£746.00
YR0008-5MG
20 mg
£1442.00
YR0008-20MG
About this Product
- SKU:
- YR0008
- Additional Names:
- L-VEGF|MVCD1|VPF
- Application:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Clonality:
- Monoclonal
- Extra Details:
- Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human VGEF
- Isotype:
- IgG1, kappa
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Antibody: Biosimilar Antibody
- Manufacturer's Data Sheet:YR0008
